NCT07239102Completed
Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
A Real-World Clinical Retrospective Study of Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
This is a clinical retrospective study that will collect and analyze clinical data from all patients treated with fumeitinib mesylate in the Oncology Department of Tiantan Hospital between January 1, 2020 and May 31, 2025. The data collection will include general demographic characteristics (gender, age, family history, smoking history, etc.), clinicopathological features, NGS test reports, fumeitinib initiation time and dosage, concomitant medications, local treatments (surgery, radiotherapy, etc.), and baseline and follow-up imaging examinations related to efficacy and safety. The study will conduct: 1) clinical data analysis; and 2) exploration of resistance-related clinical characteristics and influencing factors.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 300 (actual)
- First submitted
- 16 Nov 2025
- Start date
- 1 Jan 2020
- Primary completion date
- 1 May 2025
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07239102
What you commit to
- Study type: Observational
- Participants enrolled: 300
- From 1 Jan 2020 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Patients who cannot provide follow-up data for at least one cycle.
Who the study is looking for
- Histologically or cytologically confirmed stage IIIb-IVb NSCLC or postoperative recurrent NSCLC;
- Positive EGFR test result, which can be determined by methods such as RT-PCR/FISH/IHC/NGS from hospital laboratories or testing institutions;
- Patients aged ≥18 years;
- Patients have clinically received Firmonertinib treatment, with recorded objective efficacy evaluation and adverse reactions;
- Sign the Beijing Tiantan Hospital broad informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Li Xiaoyan Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.